PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neviani, Paolo; Harb, Jason G.; Oaks, Joshua J.; Santhanam, Ramasamy; Walker, Christopher J.; Ellis, Justin J.; Ferenchak, Gregory; Dorrance, Adrienne M.; Paisie, Carolyn A.; Eiring, Anna M.; Yihui Ma; Hsiaoyin C. Mao; Bin Zhang; Wunderlich, Mark; May, Philippa C.; Sun, Chaode; Saddoughi, Sahar A.; Bielawski, Jacek; Blum, William; Klisovic, Rebecca B.; Journal of Clinical Investigation, 2013, vol. 123, issue 10, p 4144, ISSN 00219738. ISBN 00219738.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef